ClinicalTrials.gov
public full text
Public Domain
Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1#1057376
- A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis#862179
- A Trial of Rosiglitazone for Ulcerative Colitis#67778
- ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis#979192
- PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)#1087677
Record · ID 800535
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive